Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: TRI, FDA

Therapeutic Solutions International Prepares to Apply for Emergency Use Authorization (EUA) for its FDA Phase III COVID-19 Stem Cell Therapy JadiCelltm

ELK CITY, Idaho, Aug. 16, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today initiation of preparation for filing an Emergency Use Authorization (EUA) to the FDA for JadiCellstm in treatment of COVID-19 associated lung injury. 

The EUA is a mechanism that allows FDA to help strengthen the nation's public health protections against threats such as infectious diseases by facilitating the availability and use of medical countermeasures (MCMs) needed during public health emergencies. Under this provision, the FDA may authorize unapproved medical products to be used in an emergency to treat serious or life-threatening diseases or conditions.

"The extremely promising preclinical data we are generating, as well as the previously published double blind FDA clinical trial and most recently, FDA clearance to enter Phase III, strongly supports the rationale to file for Emergency Use Authorization" said Dr. James Veltmeyer, Chief Medical Officer of the Company. "As a practicing physician, myself and my colleagues are eager to begin using these cells and potentially saving lives".

In previous studies the Company has demonstrated the superior activity of JadiCelltm to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, in an FDA double blind clinical trial the JadiCelltm was shown to be 100% effective in saving the lives of COVID-19 ICU patients1 under the age of 85. On August 5th, 2021, the FDA granted clearance for initiation of a Phase III pivotal trial using JadiCells to treat COVID-192.

"We are thankful to our Advisory Board, which includes Dr. Francesco Marincola, World Wide Head of Cell Therapy Research for Gilead, and Dr. Santosh Kesari, Principle Investigator on other stem cell trials for COVID-19, for bringing decades of national and international expertise in dealing with regulatory bodies in fast-tracking approval of cellular and gene therapies in helping us to make this monumental decision" said Timothy Dixon, President and CEO of Therapeutic Solutions International. "Given the urgent nature of the ongoing pandemic, and the early suggestions that our cells are effective against the delta variant, we are exploring and pursuing all possible avenues to bring JadiCells to the patients that need them now."

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/ 

1 Umbilical cord mesenchymal stem cells for COVID?19 acute respiratory distress syndrome: A double?blind, phase 1/2a, randomized controlled trial - Lanzoni - 2021 - STEM CELLS Translational Medicine - Wiley Online Library

2 Therapeutic Solutions International Receives FDA Clearance to Initiate Phase III Pivotal Registration Trial for JadiCelltm Universal Donor COVID-19 Therapy (prnewswire.com)



SOURCE Therapeutic Solutions International

These press releases may also interest you

at 19:29
Global advertising and marketing agency Channel Bakers announced it has partnered with Skai, a leading commerce intelligence platform, to expand the agency's suite of eCommerce solutions. Agency CEO and Founder Joshua Kreitzer said the Skai...

at 19:00
Skypod is pleased to announce their support of Breast Cancer Awareness Month alongside The National Breast Cancer Foundation with a $100 credit donation to all those who have been recently diagnosed with or who have survived breast cancer. This past...

at 19:00
Meeami Technologies (Meeami®), a pioneer and leader in audio AI, noise cancellation, speaker ID and audio analytics software, today announced that its flag ship ClearVoice noise cancellation technology is available for Contact Center agents on...

at 18:55
Blume Global, the leading provider of supply chain execution and visibility solutions, is proud to be the first to deliver logistics execution and supply chain visibility solutions completely native to Google Cloud Platform. Customers that use...

at 18:54
Apollo Career Center ("Apollo"), an adult education center located in Allen County, Ohio, recently announced that it identified and addressed a data security incident. Apollo immediately began to investigate, a cybersecurity firm was engaged, and...

at 18:49
Sprout Mortgage is strengthening its robust line of automation tools for a fully digital mortgage experience with the release of its third originator-focused mortgage tool. Sprout will unveil iAnalyze, the first non-QM bank statement analyzer tool of...

News published on 16 august 2021 at 09:00 and distributed by: